Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1990 1
1991 1
1992 2
1994 1
1997 1
2000 2
2001 1
2003 2
2004 3
2006 5
2008 4
2009 5
2010 1
2011 3
2012 6
2013 2
2014 5
2015 6
2016 6
2017 8
2018 6
2019 4
2020 2
2021 2
2022 4
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Results by year

Filters applied: . Clear all
Page 1
European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders.
Al-Toma A, Volta U, Auricchio R, Castillejo G, Sanders DS, Cellier C, Mulder CJ, Lundin KEA. Al-Toma A, et al. United European Gastroenterol J. 2019 Jun;7(5):583-613. doi: 10.1177/2050640619844125. Epub 2019 Apr 13. United European Gastroenterol J. 2019. PMID: 31210940 Free PMC article.
In addition, evaluation to exclude complications of CD, such as refractory CD or lymphoma, should be performed. The guideline also deals with other gluten-related disorders, such as dermatitis herpetiformis, which is a cutaneous manifestation of CD characteri …
In addition, evaluation to exclude complications of CD, such as refractory CD or lymphoma, should be performed. The guideline …
Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management.
Shustov A, Soma L. Shustov A, et al. Cancer Treat Res. 2019;176:127-144. doi: 10.1007/978-3-319-99716-2_6. Cancer Treat Res. 2019. PMID: 30596216 Review.
Anaplastic Large Cell Lymphomas (ALCL) are clinically aggressive and pathologically distinct lymphoid neoplasms that originate from a mature post-thymic T-cell. The contemporary World Health Organization (WHO) Classification of Haematologic Malignancies recognizes t …
Anaplastic Large Cell Lymphomas (ALCL) are clinically aggressive and pathologically distinct lymphoid neoplasms that originate from a mature …
Romidepsin for the treatment of non-Hodgkin's lymphoma.
Yazbeck VY, Grant S. Yazbeck VY, et al. Expert Opin Investig Drugs. 2015;24(7):965-79. doi: 10.1517/13543784.2015.1041586. Epub 2015 May 4. Expert Opin Investig Drugs. 2015. PMID: 25936363 Review.
AREAS COVERED: This review discusses the different HDACs and epigenetic regulation with a particular focus on the preclinical and clinical development of romidepsin in lymphoma. The review of romidepsin includes: the mechanism of action, its synergistic interaction with no …
AREAS COVERED: This review discusses the different HDACs and epigenetic regulation with a particular focus on the preclinical and clinical d …
Current treatment strategies and emerging therapies for cutaneous lymphoma.
Yonekura K. Yonekura K. J Dermatol. 2022 Feb;49(2):223-231. doi: 10.1111/1346-8138.16289. Epub 2021 Dec 27. J Dermatol. 2022. PMID: 34958516 Review.
Cutaneous lymphoma is generally treated with skin-directed therapies (SDT) during the early and localized stages. ...In recent years, many novel agents have been introduced and the strategy for systemic therapy has changed, especially for cutaneous …
Cutaneous lymphoma is generally treated with skin-directed therapies (SDT) during the early and localized stages. ...In …
Forodesine in the treatment of cutaneous T-cell lymphoma.
Lewis DJ, Duvic M. Lewis DJ, et al. Expert Opin Investig Drugs. 2017 Jun;26(6):771-775. doi: 10.1080/13543784.2017.1324569. Epub 2017 May 5. Expert Opin Investig Drugs. 2017. PMID: 28447489 Review.
Cutaneous T-cell lymphoma (CTCL) is characterized by the accumulation of neoplastic CD4+ T lymphocytes in the skin. ...Expert opinion: IV and oral formulations of forodesine have demonstrated partial activity and an acceptable safety profile in patient …
Cutaneous T-cell lymphoma (CTCL) is characterized by the accumulation of neoplastic CD4+ T lymphocytes in the sk …
Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas.
Remer M, Al-Shamkhani A, Glennie M, Johnson P. Remer M, et al. Immunotherapy. 2014;6(11):1187-206. doi: 10.2217/imt.14.94. Immunotherapy. 2014. PMID: 25496334 Review.
Tregs play an essential role in maintaining immune balance; however, in malignancy, Tregs impair host antitumor immunity and provide a favorable environment for tumors to grow. CCR4 is highly expressed by aggressive peripheral T-cell lymphomas (PTCLs), particularly …
Tregs play an essential role in maintaining immune balance; however, in malignancy, Tregs impair host antitumor immunity and provide a favor …
Emerging drugs for the treatment of cutaneous T-cell lymphoma.
Cheng M, Zain J, Rosen ST, Querfeld C. Cheng M, et al. Expert Opin Emerg Drugs. 2022 Mar;27(1):45-54. doi: 10.1080/14728214.2022.2049233. Epub 2022 Mar 8. Expert Opin Emerg Drugs. 2022. PMID: 35235473 Free PMC article. Review.
INTRODUCTION: Cutaneous T cell lymphoma (CTCL) is a rare and incurable group of non-Hodgkin lymphomas that manifest as patches, plaques, tumors, and/or erythroderma in the skin. Standard skin-directed therapies for CTCL are effective in patients …
INTRODUCTION: Cutaneous T cell lymphoma (CTCL) is a rare and incurable group of non-Hodgkin lymphomas that manif …
Romidepsin for the Treatment of Peripheral T-Cell Lymphoma.
Iyer SP, Foss FF. Iyer SP, et al. Oncologist. 2015 Sep;20(9):1084-91. doi: 10.1634/theoncologist.2015-0043. Epub 2015 Jun 22. Oncologist. 2015. PMID: 26099743 Free PMC article. Review.
Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of non-Hodgkin lymphomas associated with poor prognosis in most subtypes. ...Food and Drug Administration for the treatment of patients with cutaneous T-cell lymphoma who h …
Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of non-Hodgkin lymphomas associated with poor prognosis in m …
Moving towards biologically informed treatment strategies for T-cell lymphomas.
Stuver R, Lewis N, Dogan A, Horwitz SM. Stuver R, et al. Int J Hematol. 2023 Apr;117(4):492-503. doi: 10.1007/s12185-022-03524-4. Epub 2022 Dec 27. Int J Hematol. 2023. PMID: 36574170 Free PMC article. Review.
The rarity and biological heterogeneity of the peripheral T-cell lymphomas has made subtype- and biomarker-driven approaches challenging to realize and even more challenging to evaluate in clinical practice. Out of necessity, treatment of T-cell lympho …
The rarity and biological heterogeneity of the peripheral T-cell lymphomas has made subtype- and biomarker-driven approaches c …
Investigative drugs for the treatment of cutaneous T-cell lymphomas (CTCL): an update.
Ramelyte E, Dummer R, Guenova E. Ramelyte E, et al. Expert Opin Investig Drugs. 2019 Sep;28(9):799-809. doi: 10.1080/13543784.2019.1654995. Epub 2019 Aug 18. Expert Opin Investig Drugs. 2019. PMID: 31398295 Review.
Introduction: Cutaneous T-cell lymphoma (CTCL) is a heterogeneous group of skin-homing T-cell neoplasms, which represent approximately 75% of all primary cutaneous lymphomas. ...Larger trials are needed to better evaluate the discu …
Introduction: Cutaneous T-cell lymphoma (CTCL) is a heterogeneous group of skin-homing T-cell neop …
83 results